US 8,877,795 · Application 13/696,505 · Granted Nov 4, 2014
US 8,877,795
Identification of stabilizers of multimeric proteins
Estimated expiration
May 5, 2031
4y 230d remaining
Earliest effective filing
May 5, 2011
+ 20 years
May 5, 2031
PTA +0d
May 5, 2031
TD cap (US 9,642,838)
Mar 14, 2033
Final
May 5, 2031
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- January 23, 2013
- Earliest effective filing
- May 5, 2011
- Issue date
- November 4, 2014
- PTA
- 0 days
- Base expiry (before PTA)
- May 5, 2031
May 5, 2011 + 20 years = May 5, 2031
- National stage entry of application PCTUS2011035350, filed May 5, 2011
- PRO61/332,638 — Provisional — not used for base term
- PRO61/332,638 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to March 14, 2033 (earliest expiring referenced patent: US 9,642,838)
US 13,696,505
Could not resolve calculation details
US 9,642,838· Application 14/876,447Capping patent
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
- Filing date
- Oct 6, 2015
- Earliest effective filing
- Mar 14, 2013
- Issue date
- May 9, 2017
- PTA
- 0 days
- Calculated expiration
- Mar 14, 2033
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Mar 14, 2013 + 20y = Mar 14, 2033
US 9,913,826· Application 15/480,139
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
- Filing date
- Apr 5, 2017
- Earliest effective filing
- Mar 14, 2013
- Issue date
- Mar 13, 2018
- PTA
- 0 days
- Calculated expiration
- Mar 14, 2033
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Mar 14, 2013 + 20y = Mar 14, 2033
US 10,398,681· Application 15/883,750
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
- Filing date
- Jan 30, 2018
- Earliest effective filing
- Mar 14, 2013
- Issue date
- Sep 3, 2019
- PTA
- 0 days
- Calculated expiration
- Mar 14, 2033
Continuation of 15/480,139, filed Apr 5, 2017, issued as US 9,913,826
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Mar 14, 2013 + 20y = Mar 14, 2033
US 10,842,777· Application 16/510,574
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
- Filing date
- Jul 12, 2019
- Earliest effective filing
- Mar 14, 2013
- Issue date
- Nov 24, 2020
- PTA
- 0 days
- Calculated expiration
- Mar 14, 2033
Continuation of 15/883,750, filed Jan 30, 2018, issued as US 10,398,681
Continuation of 15/480,139, filed Apr 5, 2017, issued as US 9,913,826
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Continuation of 15/480,139, filed Apr 5, 2017, issued as US 9,913,826
Continuation of 14/876,447, filed Oct 6, 2015, issued as US 9,642,838
Continuation of 13/830,731, filed Mar 14, 2013, issued as US 9,169,214
Mar 14, 2013 + 20y = Mar 14, 2033
Notes (1)
- [TD_REFS_TRUNCATED] Found 11 TD references; resolving first 5 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 13/696,505 · US 8,877,795
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,877,795: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8877795Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.